Preventing Vascular Complications in Type Diabetes Muscle Metabolic Monitoring

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK112497-01
Agency Tracking Number: R41DK112497
Amount: $183,142.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDDK
Solicitation Number: PA14-059
Timeline
Solicitation Year: 2014
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-18
Award End Date (Contract End Date): 2019-09-17
Small Business Information
220 RIVERBEND RD, Athens, GA, 30602-1511
DUNS: 079414542
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 KEVIN MCCULLY
 (215) 222-2222
 mccully@uga.edu
Business Contact
 KEVIN MCCULLY
Phone: (706) 542-1129
Email: mccully@uga.edu
Research Institution
 UNIVERSITY OF GEORGIA
 TUCKER HALL 310 EAST CAMPUS RD ROOM 409
ATHENS, GA, 30602-1589
 Nonprofit college or university
Abstract
Project Summary Abstract While much has been accomplished in managing hyperglycemia morbidity and mortality in patients with type diabetes T D often results from cardiovascular complications Evidence suggests peripheral artery disease and skeletal muscle mitochondrial dysfunction One reason is the lack of reliable tools to characterize skeletal muscle microcirculation and mitochondrial capacity key elements in regulating effective mobility and insulin use in health and disease Our central hypothesis is that near infrared spectroscopy NIRS based technology can uniquely assess skeletal muscle function in patients with T D because it accounts for macrovascular microvascular and pharmacologic influences on muscle function In addition the attributes of this technology are inherently valuable to the study and care of complications of type diabetes patients because it is safe reliable non invasive and scalable for widespread use To that end we propose the following specific aims Specific Aim we will develop an automated analysis platform for NIRS derived measures of skeletal muscle mitochondrial capacity Specific Aim we will define the value proposition of NIRS based microvascular and mitochondrial assessment Analysis platform validation will include test retest NIRS measurements and comparison measurement of microcirculation and mitochondrial using magnetic resonance imaging MRI and P magnetic resonance spectroscopy MRS Patients with type diabetes n and aged matched healthy subjects n will be evaluated Our value proposition will be defined through customer discovery with internists endocrinologists and cardiologists The endpoint for the second aim will be a detailed testing protocol and fully automated web based analysis program including error analysis and error correction recommendations We will provide beta testing access to the automated analysis product End user data will inform the next phase of product development a fully integrated and automated data acquisition and analysis platform Importantly Infrared Rx Inc will engage the expertise of team members with healthcare software and marketing expertise to drive the customer discovery process The NIRS based technology is noninvasive inexpensive and portable By making the methods simple to perform and obtain results NIRS has the potential to be a clinical evaluation tool for patients with Type Diabetes Project Narrative Type Diabetes results in impairments in vascular and mitochondrial function which contributes to progression of the disease and poor health outcomes We will develop an automated analysis platform and define the value proposition for NIRS based microvascular and mitochondrial assessments in patients with Type Diabetes

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government